sorafenib has been researched along with Cardiomyopathies in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
| Cheng, S; Moslehi, J; Uraizee, I | 1 |
| Han, SH; Kang, H; Park, H; Park, K | 1 |
3 other study(ies) available for sorafenib and Cardiomyopathies
| Article | Year |
|---|---|
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |
Reversible cardiomyopathy associated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cardiomyopathies; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiomyopathies; Coronary Angiography; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |